Indication: For mild and moderate infections caused by sensitive bacteria. Upper respiratory tract infection, purulent streptococcal pharyngitis/tonsillitis. Note: Intramuscular penicillin should be selected for the treatment and prevention of streptococcal infections (including the prevention of rheumatic fever). Although cefprozil is generally effective in clearing purulent streptococci in the nasopharynx, there is currently no data available for the use of cefprozil in the prevention of secondary rheumatic fever. Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella catarrhalis (including β-lactamase-producing strains). Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella catarrhalis (including β-lactamase-producing strains). Lower respiratory tract infection, secondary bacterial infection of acute bronchitis and acute exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella catarrhalis (including β-lactamase-producing strains). Skin and skin tissue infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes are uncomplicated, but abscesses usually require surgical drainage.

Indication: It is used for the following mild and moderate infections caused by sensitive bacteria: 1. Upper respiratory tract infection. 2. Lower respiratory tract infection. 3. Skin and skin soft tissue infection.

Indication: It is used for the following mild and moderate infections caused by sensitive bacteria: 1. Upper respiratory tract infection. 2. Lower respiratory tract infection. 3. Skin and skin soft tissue infection.

Indication: For the following mild and moderate infections caused by sensitive bacteria: 1. Upper respiratory tract infection, Streptococcus pyogenes pharyngitis/tonsillitis. Note: Intramuscular penicillin should usually be used to treat and prevent streptococcal infections (including prevention of rheumatic fever). Although cefprozil can generally effectively eliminate Streptococcus pyogenes in the nasopharynx, there is currently no reference data on the use of cefprozil to prevent secondary rheumatic fever. Otitis media and acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains) and Moraxella catarrhalis (including β-lactamase-producing strains). 2. Lower respiratory tract infection, secondary bacterial infection of acute bronchitis and acute exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains) and Moraxella catarrhalis (including β-lactamase-producing strains). 3. Uncomplicated skin and skin soft tissue infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes, but abscesses usually require surgical drainage. Bacterial culture and drug sensitivity testing should be performed when appropriate to determine the sensitivity of the pathogen to cefprozil.

Indication: It is used for the following mild and moderate infections caused by sensitive bacteria: upper respiratory tract infections (pyogenic streptococcal pharyngitis/tonsillitis, otitis media, acute sinusitis), lower respiratory tract infections (acute bronchitis secondary to bacterial infection and acute exacerbation of chronic bronchitis), skin and soft tissue infections.

Indication: Antibiotic drugs. It has antibacterial effects on Staphylococcus aureus, penicillin-resistant Staphylococcus aureus, Streptococcus, Pneumococcus, Escherichia coli, etc. This product is easy to absorb after oral administration and is mostly excreted in urine in its original form. It is mainly used for staphylococcal soft tissue infection, streptococcal pharyngitis, pneumococcal lobar pneumonia and urinary tract infection.

Indication: INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Community-Acquired Pneumonia Haemophilus influenzae Haemophilus parainfluenzae Streptococcus pneumoniae Moraxella catarrhalis CLINICAL STUDIES Acute Exacerbations of Chronic Bronchitis Haemophilus influenzae Haemophilus parainfluenzae Streptococcus pneumoniae Moraxella catarrhalis Acute Maxillary Sinusitis Haemophilus influenzae Streptococcus pneumoniae Moraxella catarrhalis NOTE: Pediatric Use DOSAGE AND ADMINISTRATION Streptococcus pyogenes CLINICAL STUDIES NOTE: S. pyogenes Staphylococcus aureus Streptococcus pyogenes Acute Bacterial Otitis Media Haemophilus influenzae Streptococcus pneumoniae Moraxella catarrhalis Streptococcus pyogenes CLINICAL STUDIES S. pyogenes Staphylococcus aureus Streptococcus pyogenes.
Community-Acquired Bacterial Pneumonia
In a controlled, double-blind study in adults and adolescents conducted in the U.S., cefdinir BID was compared with cefaclor 500 mg TID. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained: U.S. Community-Acquired Pneumonia Study Cefdinir vs Cefaclor Cefdinir BID Cefaclor TID Outcome Clinical Cure Rates 150/187 (80%) 147/186 (79%) Cefdinir equivalent to control Eradication Rates Overall 177/195 (91%) 184/200 (92%) Cefdinir equivalent to control S. pneumoniae 31/31 (100%) 35/35 (100%) H. influenzae 55/65 (85%) 60/72 (83%) M. catarrhalis 10/10 (100%) 11/11 (100%) H. parainfluenzae 81/89 (91%) 78/82 (95%) In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir BID was compared with amoxicillin/clavulanate 500/125 mg TID. Using strict evaluability and clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained: European Community-Acquired Pneumonia Study Cefdinir vs Amoxicillin/Clavulanate Cefdinir BID Amoxicillin/ Clavulanate TID Outcome Clinical Cure Rates 83/104 (80%) 86/97(89%) Cefdinir not equivalent to control Eradication Rates S. pneumoniae 42/44 (95%) 43/44 (98%) H. influenzae 26/35 (74%) 21/26 (81%) M. catarrhalis 6/6 (100%) 8/8 (100%) H. parainfluenzae 11/11 (100%) 12/12 (100%)
Streptococcal Pharyngitis/Tonsillitis
In four controlled studies conducted in the United States, cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir QD or BID to penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/clinical response criteria 5 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained: Pharyngitis/Tonsillitis Studies Cefdinir (10 days) vs Penicillin (10 days) Study Efficacy Parameter Cefdinir QD Cefdinir BID Penicillin QID Outcome Adults/ Adolescents Eradication of S. pyogenes 192/210 (91%) 199/217 (92%) 181/217 (83%) Cefdinir superior to control Clinical Cure Rates 199/210 (95%) 209/217 (96%) 193/217 (89%) Cefdinir superior to control Pediatric Patients Eradication of S. pyogenes 215/228 (94%) 214/227 (94%) 159/227 (70%) Cefdinir superior to control Clinical Cure Rates 222/228 (97%) 218/227 (96%) 196/227 (86%) Cefdinir superior to control Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir BID to 10 days of penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/clinical response criteria 4 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained: Pharyngitis/Tonsillitis Studies Cefdinir (5 days) vs Penicillin (10 days) Study Efficacy Parameter Cefdinir BID Penicillin QID Outcome Adults/ Adolescents Eradication of S. pyogenes 193/218 (89%) 176/214 (82%) Cefdinir equivalent to control Clinical Cure Rates 194/218 (89%) 181/214 (85%) Cefdinir equivalent to control Pediatric Patients Eradication of S. pyogenes 176/196 (90%) 135/193 (70%) Cefdinir superior to control Clinical Cure Rates 179/196 (91%) 173/193 (90%) Cefdinir equivalent to control

Indication: INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. caused by Haemophilusinfluenzae Haemophilusparainfluenzae Streptococcus pneumoniae Moraxella catarrhalis CLINICAL STUDIES caused by Haemophilusinfluenzae Haemophilusparainfluenzae Streptococcus pneumoniae Moraxella catarrhalis caused by Haemophilusinfluenzae Streptococcus pneumoniae Moraxella catarrhalis NOTE: Pediatric Use DOSAGE AND ADMINISTRATION caused by Streptococcus pyogenes CLINICAL STUDIES NOTE: S. pyogenes caused by Staphylococcus aureus Streptococcus pyogenes caused by Haemophilusinfluenzae Streptococcus pneumoniae Moraxella catarrhalis caused by Streptococcus pyogenes CLINICAL STUDIES NOTE: S. pyogenes caused by Staphylococcus aureus Streptococcus pyogenes.
Community-Acquired Bacterial Pneumonia
In a controlled, double-blind study in adults and adolescents conducted in the U.S., cefdinir b.i.d. was compared with cefaclor 500 mg t.i.d.. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained: U.S. Community-Acquired Pneumonia Study Cefdinir vs Cefaclor Cefdinirb.i.d. Cefaclort.i.d. Outcome Clinical Cure Rates 150/187 (80%) 147/186 (79%) Cefdinir equivalent to control Eradication Rates Overall 177/195 (91%) 184/200 (92%) Cefdinir equivalent to control S. pneumoniae 31/31 (100%) 35/35 (100%) H. influenzae 55/65 (85%) 60/72 (83%) M. catarrhalis 10/10 (100%) 11/11 (100%) H. parainfluenzae 81/89 (91%) 78/82 (95%) In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir b.i.d. was compared with amoxicillin/clavulanate 500/125 mg t.i.d.. Using strict evaluability and clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained: European Community-Acquired Pneumonia Study Cefdinir vs Amoxicillin/Clavulanate Cefdinirb.i.d. Amoxicillin/ Clavulanatet.i.d. Outcome Clinical Cure Rates 83/104 (80%) 86/97 (89%) Cefdinir not equivalent to control Eradication Rates Overall 85/96 (89%) 84/90 (93%) Cefdinir equivalent to control S. pneumoniae 42/44 (95%) 43/44 (98%) H. influenzae 26/35 (74%) 21/26 (81%) M. catarrhalis 6/6 (100%) 8/8 (100%) H. parainfluenzae 11/11 (100%) 12/12 (100%)
Streptococcal Pharyngitis/Tonsillitis
In four controlled studies conducted in the United States, cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir q.d. or b.i.d. to penicillin 250 mg or 10 mg/kg q.i.d.. Using strict evaluability and microbiologic/clinical response criteria 5 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained: Pharyngitis/Tonsillitis Studies Cefdinir (10 days) vs Penicillin (10 days) Study Efficacy Parameter Cefdinir q.d. Cefdinir b.i.d. Penicillin q.i.d. Outcome Adults/ Adolescents Eradication of S. pyogenes Clinical Cure Rates 192/210 (91%) 199/217 (92%) 181/217 (83%) Cefdinir superior to control 199/210 (95%) 209/217 (96%) 193/217 (89%) Cefdinir superior to control Pediatric Patients Eradication of S. pyogenes Clinical Cure Rates 215/228 (94%) 214/227 (94%) 159/227 (70%) Cefdinir superior to control 222/228 (97%) 218/227 (96%) 196/227 (86%) Cefdinir superior to control Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir b.i.d. to 10 days of penicillin 250 mg or 10 mg/kg q.i.d.. Using strict evaluability and microbiologic/clinical response criteria 4 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained: Pharyngitis/Tonsillitis Studies Cefdinir (5 days) vs Penicillin (10 days) Study Efficacy Parameter Cefdinir b.i.d. Penicillin q.i.d. Outcome Adults/ Adolescents Eradication of S. pyogenes Clinical Cure Rates 193/218 (89%) 176/214 (82%) Cefdinir equivalent to control 194/218 (89%) 181/214 (85%) Cefdinir equivalent to control Pediatric Patients Eradication of S. pyogenes Clinical Cure Rates 176/196 (90%) 135/193 (70%) Cefdinir superior to control 179/196 (91%) 173/193 (90%) Cefdinir equivalent to control